

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently amended): A method for the inhibition of post-operative adhesion formation in a body between tissue surfaces ~~in an internal body cavity~~ having which have been subjected to a surgical procedure comprising locally administering a composition comprising a delivery vehicle containing Tranilast, or an analog thereof, directly onto said tissue surfaces at the surgical site ~~in said body cavity~~ in amounts and under conditions therapeutically effective to inhibit formation of adhesions thereon.

Claim 2 (Currently amended): The method of claim 1 wherein said ~~Tranilast or analog thereof is administered in cooperation with a~~ delivery vehicle is suitable for use in the local, non-systemic administration of a therapeutic agent to the body.

Claim 3 (Original): The method of claim 2 wherein said delivery vehicle is selected from the group consisting of microcapsules, microspheres, barriers, liposomes, lipid foams, solutions, compositions, osmotic pumps, fibers, filaments, gels, foams and films.

Claim 4 (Original): The method of claim 3 wherein said barrier is absorbable.

Claim 5 (Original): The method of claim 1 wherein said Tranilast is administered in combination with a therapeutic agent, said therapeutic agent administered in

an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent.

Claim 6 (Original): The method of claim 5 wherein said therapeutic agent is selected from the group consisting of an anti-platelet, an anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.

Claim 7 (Original): The method of claim 1 wherein said Tranilast analog is selected from the group consisting of N-(2-Acetyl-4,5-dimethoxyphenyl)(4-((phenylamino)-carbonylamino)phenyl)formamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-2-(4-((phenylamino)-carbonylamino)phenyl)ethanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((phenylamino)-carbonylamino)phenyl)prop-2-enamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((phenylamino)-carbonylamino)phenyl)-propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-4-(4-((phenylamino)-carbonylamino)phenyl)butanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(phenylcarbonylamino)-carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(2-phenylacetyl amino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(phenoxy carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2-nitrophenyl)amino)carbonylamino)-phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-nitrophenyl)-amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-nitrophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2-aminophenyl)amino)carbonylamino)phenyl)-propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-aminophenyl)amino)-carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-fluorophenyl)amino)carbonylamino)phenyl)-propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-acetylphenyl)-amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-methylphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-

dimethoxyphenyl)-3-(4-(((4-methoxyphenyl)amino)carbonylamino)-phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3,4,5-trimethoxyphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-pyridyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((benzylamino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((butylamino)carbonylamino)phenyl)propanamide and N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((cyclohexylamino)carbonylamino)phenyl)propanamide.

Claim 8 (Original): The method of claim 1 wherein said Tranilast or analog thereof is administered in a single dose.

Claim 9 (Original): The method of claim 1 wherein said Tranilast or analog thereof is administered by sustained release.

Claim 10 (Original): The method of claim 1 wherein said Tranilast or analog thereof is administered by burst/sustained release.

Claim 11 (Original): The method of claim 1 wherein said Tranilast or analog thereof is administered at a level of from about 0.01 milligram per kilogram of the body to about 3,000 milligram per kilogram of the body.

Claim 12 (Original): The method of claim 1 further comprising administering Tranilast systemically to said body prior to said surgical procedure.

Claim 13 (Currently amended): The method of claim 1 wherein Tranilast is additionally administered systemically to said body prior to said surgical procedure in amounts and for a time effective to increase inhibition for formation of adhesions in said body when compared to local administration of Tranilast

Application No.: 10/714,719
Dated: November 19, 2008
Response to Official Action of August 19, 2008

directly to onto said tissue surfaces at the surgical site ~~in-said body cavity~~ in said body without said systemic administration.

Claims 14-41 (Canceled).